Search results for " Administration"

showing 10 items of 4299 documents

Die operative Therapie einer segmentalen, primären intestinalen Lymphangiektasie des Jejunums mit ausgeprägtem Chylaskos

2011

Primary intestinal lymphangiectasia (PIL) is a protein-losing, exsudative gastroenteropathy causing lymphatic obstruction. Diagnosis depends on clinical examination and histological findings. Conservative treatment modalities include a low-fat diet and enteral nutritional therapy in order to reduce enteric protein loss and to improve fat metabolism. Other treatment options consist of administration of antiplasmin or octreotide to lower lymph flow and secretion. We report on a 58-year-old patient who underwent exploratory laparotomy due to a worsening physical status, recurrent chylaskos and leg oedema under conservative dietary therapy. Intraoperative findings showed a typical PIL of the je…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryExploratory laparotomymedicine.medical_treatmentGastroenterologyOctreotidePhysical examinationAnastomosisGastroenterologyEnteral administrationJejunummedicine.anatomical_structureInternal medicineAscitesmedicineMedical nutrition therapymedicine.symptombusinessmedicine.drugZeitschrift für Gastroenterologie
researchProduct

Clinical pharmacokinetics of atenolol — A review

1982

Atenolol is a hydrophilic betareceptor blocking drug, which is predominantly eliminated via the kidneys, only about 5% of the atenolol is metabolised by the liver. After oral administration atenolol is incompletely absorbed from the intestine, so about 50% of the beta blocker are finally biovailable. In plasma only 3% of atenolol are protein-bound. There exists a linear relationship between the atenolol plasma levels and the degree of beta blocking effect measured by inhibition of the exercise-induced tachycardia. No correlation was found between plasma levels of atenolol and blood pressure lowering activity of the drug. After oral administration elimination half life of atenolol is calcula…

medicine.medical_specialtymedicine.drug_classAdministration OralBiological AvailabilityRenal functionPharmacologyKidneyIntestinal absorptionPropanolaminesPharmacokineticsRenal DialysisOral administrationInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)cardiovascular diseasesBeta blockerPharmacologyChemistryLiver DiseasesKidney metabolismAtenololKineticsEndocrinologyAtenololIntestinal AbsorptionInjections IntravenousKidney DiseasesBiological half-lifecirculatory and respiratory physiologymedicine.drugEuropean Journal of Drug Metabolism and Pharmacokinetics
researchProduct

Maintenance therapy in gastro-oesophageal reflux disease.

2005

Gastro-oesophageal reflux disease (GORD) is a chronic condition. Symptom control and the maintenance of healing of erosive oesophagitis, if present, are important topics. In patients responding to a proton pump inhibitor (PPI) and showing no treatment symptoms it is appropriate to consider long-term treatment strategies, whether continuous, intermittent or on demand. Maintenance PPI therapy is well tolerated for up to 10 years of continuous use. Furthermore, tachyphylaxis does not occur during long-term maintenance PPI therapy. Previous concerns about risks of long-term PPI therapy in Heliobacter pylori-negative or H. pylori-positive patients have not materialized, while no cases of intesti…

medicine.medical_specialtymedicine.drug_classProton-pump inhibitorGastroenterologyDrug Administration ScheduleEsomeprazoleHiatal herniaPharmacotherapyMaintenance therapyInternal medicinemedicineHumansPharmacology (medical)SurvivorsSurgical teambusiness.industryEsophageal diseaseDecision TreesHeartburnEndoscopyProton Pump Inhibitorsmedicine.diseaseAnti-Ulcer Agentsdigestive system diseasesGastroesophageal Refluxmedicine.symptombusinessmedicine.drugDrugs
researchProduct

Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials.

1999

The purpose of this study was to evaluate the clinical usefulness of surrogate markers of the interferon effect (i.e., alanine aminotransferase levels and serum HCV-RNA status) as predictors of long term response, and to identify the optimal schedule of treatment for patients with chronic hepatitis C by means of meta-analysis.Pertinent randomized clinical trials and prospective studies were selected using MEDLINE (1986-1996), a reference list from published articles or reviews. Twenty-six prospective studies reporting data on surrogate markers of interferon response were selected. Thirty-nine trials comparing interferon alpha to no treatment and 25 trials comparing different schedules of in…

medicine.medical_specialtymedicine.medical_treatmentHepatitis C virusHepacivirusAlpha interferonHepacivirusmedicine.disease_causeGastroenterologyDrug Administration Schedulelaw.inventionFlaviviridaeChronic hepatitisRandomized controlled triallawInternal medicinemedicineHumansInterferon alfaRandomized Controlled Trials as TopicHepatologybiologybusiness.industryGastroenterologyInterferon-alphaAlanine TransaminaseImmunotherapyHepatitis C Chronicbiology.organism_classificationImmunologyRNA Viralbusinessmedicine.drugThe American journal of gastroenterology
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Different ways to organize the processes of financial administration : a field study of medium-sized Finnish companies

2011

This research concentrates on exploring the ways how financial administration is currently organized in medium-sized companies in Finland. Decentralization, centralization and outsourcing are options that are available to different-sized companies. The study was executed as a field study in seven medium-sized Finnish companies that represent different branches. Furthermore, the research method was qualitative theme interview. As large companies have already established their financial service centers and small enterprises have outsourced their financial administration to bookkeeping agencies, medium-sized companies are located between the two, finding a way that is suitable for their strate…

medium-sized companyhajautusprosessitdecentralizationulkoistaminenprocessesfinancial administrationpalvelukeskuksetcentralizationoutsourcingtaloushallintokeskitysservice centerpienet ja keskisuuret yritykset
researchProduct

Enseignements d'une meta-analyse sur le lien participation budgétaire - performance managériale

2009

This meta-analysis is a critical comparison of three of quantitative synthesis. It applies some propositions of the Potsdam international consultation on meta-analysis, in the field of management control. Study design. After a traditional narrative review, three meta-analysis methodologies for the synthesis of articles with heterogeneous methodologies and fields are presented. After a short critical presentation of our results with “box score” and p-values combination methods, we show the result of best-evidence synthesis and its stability as recommended at the Potsdam international consultation on meta-analysis. Results. The results of methods of meta-analysis implemented do not make it po…

meta-analysissynthèse des meilleurs étudesméthodes des votesmanagerial performanceperformance managériale[SHS.GESTION]Humanities and Social Sciences/Business administrationbox score methodsbudgetary participationméta-analyseparticipation budgétaire[SHS.GESTION] Humanities and Social Sciences/Business administrationbest-evidence synthesis
researchProduct

Oral contraceptives in the prevention of endometrioma recurrence: does the different progestins used make a difference?

2013

""The primary aim of the study was to analyze the endometrioma recurrence rate in patients who underwent laparoscopic excision followed by postoperative long-term regimen of oral contraceptives (OCs).. . MATERIALS AND METHODS: 168 patients who underwent a conservative laparoscopic surgery for endometrioma, during the period between September 2009 and August 2010 in three university hospitals were studied. A long-term OCs therapy was offered to all women following surgery. Patients were randomly divided into three groups according to different progestins used (desogestrel, gestodene, dienogest). Women who refused a postoperative hormonal therapy served as control. Follow-up visits and transv…

minimally invasive gynecologic surgeryAdultmedicine.medical_specialtyEndometriosis endometrioma recurrencee oral contraceptives minimally invasive gynecologic surgery progestins dienogest.AdolescentNorpregnenesendometrioma recurrenceeEndometriosisEndometriosisKaplan-Meier EstimateDrug Administration Schedulelaw.inventionYoung Adultchemistry.chemical_compoundRandomized controlled triallawSecondary PreventionHumansNandroloneMedicineIn patientOvarian DiseasesYoung adultLaparoscopyoral contraceptivesDesogestrelmedicine.diagnostic_testbusiness.industryObstetricsObstetrics and GynecologyEndometriosis Endometrioma recurrence Oral contraceptives Minimally invasive gynaecologic surgery Progestins DienogestGeneral MedicineLaparoscopic excisionmedicine.diseaseCombined Modality TherapySurgeryRegimenTreatment OutcomeDienogestchemistryprogestinsdienogestFemaleLaparoscopybusinessContraceptives OralFollow-Up Studies
researchProduct

The division of domestic work among dual-career and other dual-earner couples in Finland

2015

This study compares the division of domestic work among dual-career and other dual-earner couples. We examine whether gender attitudes, relative resources and working time explain the differences between dual-career and other dual-earner couples. We define dual-career couples as those in which both spouses are professionals and/or managers. The division of housework is important for these couples because of the intense pressures of work. We hypothesise that domestic work is more equally shared among dual-career couples than among other dual-earner couples. The quantitative analyses are based on the Finnish data from the 2010 European Social Survey (N = 493). The qualitative data consist of …

mixed methodsSociology and Political ScienceDomestic workdomestic workQualitative propertyDevelopmentgender attitudesSuomigender050602 political science & public administrationtyöuraSociologyFinlandkotityö05 social sciencesGeneral Social Sciencesta5142Working time0506 political scienceEuropean Social SurveyDual (category theory)Work (electrical)050902 family studies8. Economic growth0509 other social sciencesperheetSocial psychologydual-earner/career couplesCommunity, Work & Family
researchProduct

Continuous subcutaneous Insulin infusion leads to immediate, table, and long-term changes in metabolic control

2008

Background:  Evaluations of continuous subcutaneous insulin infusion (CSII) usually focus on one pre- and one post-CSII measurement to assess metabolic therapy outcome. Aim:  Extending this research, the aim of the present study was to provide a more fine-grained analysis of achieved glycaemic control. Methods:  In 52 patients with type 1 diabetes (mean age of 37.85 years at CSII begin; s.d. ± 12.41), haemoglobin A1c (HbA1c) levels were assessed every 3 months over a period of 5 years (1 year before and 4 years after the introduction of CSII). Mixed models were utilized to describe changes in glycaemic control. Results:  The pre–post course showed that already in the first quarter, a statis…

mixed modelsAdultBlood GlucoseMalemedicine.medical_specialtyPediatricstype 1 diabetesEndocrinology Diabetes and MetabolismModels BiologicalDrug Administration ScheduleTimeHba1c levelEndocrinologyDiabetes mellitusInternal Medicinemedicinefollow upHumansHypoglycemic AgentsInsulinAge of OnsetGlycated HemoglobinType 1 diabetesHaemoglobin A1cbusiness.industry10093 Institute of PsychologyCSIIMean ageInfusion Pumps ImplantableMiddle AgedPrognosismedicine.diseaseSubcutaneous insulinSurgery1310 Endocrinologylong-term changes2712 Endocrinology Diabetes and MetabolismDiabetes Mellitus Type 1Treatment Outcome2724 Internal MedicineMetabolic control analysisFemalebusiness150 PsychologyFollow-Up StudiesMetabolic therapy
researchProduct